Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 2 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Squamous Non-Small Cell Lung Cancer 1 Squamous Cell Carcinoma of Head and Neck 1 Prostatic Neoplasms 1 Non-Muscle Invasive Bladder Neoplasms 1 Lymphoma, Large B-Cell, Diffuse 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Non-Small-Cell Lung 1 Cancer Pain 1 Breast Neoplasms 1 Biliary Tract Neoplasms 1

Interventions

Trastuzumab 209 Paclitaxel 187 Fulvestrant 161 Capecitabine 150 Docetaxel 136 Letrozole 127 exemestane 92 palbociclib 76 Anastrozole 75 Cyclophosphamide 71 Lapatinib 69 Gemcitabine 66 Bevacizumab 66 pertuzumab 61 pembrolizumab 60 ribociclib 59 Carboplatin 59 abemaciclib 53 eribulin 48 Doxorubicin 45 Vinorelbine 41 Everolimus 41 Ado-Trastuzumab Emtansine 41 Tamoxifen 40 130-nm albumin-bound paclitaxel 34 Injections 31 trastuzumab deruxtecan 30 Albumin-Bound Paclitaxel 26 olaparib 24 Alpelisib 24

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Breast Neoplasms × Antibodies × Clear all

NCT03280563 2025-11-10

MORPHEUS HR+BC

Hoffmann-La Roche

Phase 1/2 Completed

144 enrolled 25 charts

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡